Incyte Medical Monitor

Trials

Studies that name Incyte Medical Monitor as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 21:47 UTC. Open this list on ClinicalTrials.gov

• Ph2
  NCT07862998 · A Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma With FGFR2 Fusion or Rearrangements After at Least 1 Prior Line of Systemic Therapy

  Incyte Corporation · not yet recruiting · Unresectable Cholangiocarcinoma, Advanced/Metastatic Cholangiocarcinoma · study director
• Ph1
  NCT07854249 · A Study to Evaluate the Pharmacokinetics and Safety of INCB161734 in Participants With Impaired Renal Function and Participants on Hemodialysis

  Incyte Corporation · not yet recruiting · Renal Insufficiency, Kidney Diseases · study director
• Ph1
  NCT07853040 · A Study to Evaluate the Pharmacokinetics and Safety of INCB161734 in Participants With Hepatic Impairment

  Incyte Corporation · not yet recruiting · Hepatic Insufficiency, Liver Diseases · study director
• Ph2
  NCT07823322 · A Study to Evaluate INCA33890 in the Treatment of Circulating Tumor DNA-Positive Stage II/III Microsatellite Stable Colorectal Cancer After Curative Resection and Chemotherapy

  Incyte Corporation · not yet recruiting · CRC (Colorectal Cancer) · study director
• Ph1
  NCT07814404 · A Study to Assess the Mass Balance, Pharmacokinetics, and Metabolite Profiles of a Single Oral Dose of [14C]-INCB161734 in Healthy Male Participants

  Incyte Corporation · completed · Healthy Participants · study director
• Ph3
  NCT07797283 · Phase 3 Study of INCB123667 Plus Bevacizumab Versus Bevacizumab Alone as First-Line Maintenance Therapy in Ovarian Cancer Overexpressing Cyclin E1

  Incyte Corporation · not yet recruiting · Ovarian Cancer · study director
• Ph3
  NCT07623200 · A Phase 3 Study of INCA033989 Versus Best Available Therapy in Participants With Essential Thrombocythemia

  Incyte Corporation · recruiting · Essential Thrombocythemia · study director
• Ph1
  NCT07588139 · A Study to Evaluate Dermal Open-Flow Microperfusion and Plasma Pharmacokinetic Study of Multiple Doses of Oral Povorcitinib or Topical Ruxolitinib Cream in Healthy Adult Participants

  Incyte Corporation · completed · Healthy Participants · study director
• Ph1
  NCT07559396 · A Study to Assess the Safety and Pharmacokinetics of INCB123667 When Administered Orally to Adult Participants With Severe Renal Impairment or End Stage Renal Disease

  Incyte Corporation · recruiting · Renal Impairment · study director
• Ph1
  NCT07559474 · A Study to Assess the Safety and Pharmacokinetics of INCB123667 When Administered Orally to Adult Participants With Moderate or Severe Hepatic Impairment

  Incyte Corporation · recruiting · Hepatic Insufficiency, Liver Diseases · study director
• Ph3
  NCT07522073 · A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma

  Incyte Corporation · recruiting · Solid Tumors · study director
• Ph1
  NCT07448155 · A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of INCA033989 Following Subcutaneous or Intravenous Administration in Healthy Adult Participants

  Incyte Corporation · active not recruiting · Healthy Participants · study director
• Ph1
  NCT07441694 · Study of INCA036978 in Participants With Myeloproliferative Neoplasms

  Incyte Corporation · recruiting · Myeloproliferative Neoplasms · study director
• Ph3
  NCT07284849 · A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer

  Incyte Corporation · recruiting · CRC (Colorectal Cancer) · study director
• Ph1
  NCT07218744 · Study Assessing the Mass Balance, Pharmacokinetics, and Metabolite Profiles of a Single Oral Dose of [14C]-INCB123667 in Healthy Male Participants

  Incyte Corporation · completed · Healthy Participants · study director
• Ph2
  NCT07213973 · Pharmacokinetics, Safety, and Efficacy of Povorcitinib in Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa

  Incyte Corporation · recruiting · Hidradenitis Suppurativa (HS) · study director
• Ph3
  NCT07214779 · Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression

  Incyte Corporation · recruiting · Ovarian Cancer · study director
• Ph2
  NCT07124078 · A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Disease After at Least 2 Prior Lines of Systemic Therapy (AGAVE-256)

  Incyte Corporation · recruiting · Chronic Graft-versus-host-disease · study director
• Ph2
  NCT07104565 · Study to Assess the Safety and Tolerability of Tafasitamab in Adult Participants With Primary Autoimmune Blood Cell Disorders

  Incyte Corporation · recruiting · Immune Thrombocytopenia · study director
• Ph1
  NCT07049575 · Study to Evaluate the Maximal Use of Ruxolitinib Cream in Adult and Adolescent Participants With Hidradenitis Suppurativa

  Incyte Corporation · recruiting · Hidradenitis Suppurativa · study director
• Ph1
  NCT07039929 · Study to Assess the Safety, Tolerability, and Pharmacokinetics of INCB000631 When Administered Orally to Healthy Adult Participants

  Incyte Corporation · terminated · Healthy Participants · study director
• Ph2
  NCT07023627 · A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression

  Incyte Corporation · recruiting · Ovarian Cancer · study director
• Ph1
  NCT07018635 · A Study to Assess the Effect of Itraconazole, Rifampin, and Acid-Reducing Agents on INCB161734 Pharmacokinetics When Administered Orally in Healthy Participants

  Incyte Corporation · completed · Healthy Participants · study director
• Ph1
  NCT07008118 · A Study to Evaluate INCA035784 in Participants With Myeloproliferative Neoplasms

  Incyte Corporation · recruiting · Myeloproliferative Neoplasms · study director
• N/A
  NCT06934980 · A Study to Evaluate Microneedle-based Collection of Dermal Interstitial Skin Fluid in Healthy Participants and Atopic Dermatitis Participants

  Incyte Corporation · completed · Atopic Dermatitis, Healthy Volunteers · study director
• Ph1
  NCT06909162 · A Study to Evaluate the Effect of Food on the Single-Dose Pharmacokinetics and a Drug-Drug Interaction Evaluation of Itraconazole and Carbamazepine on INCB123667 When Administered Orally to Healthy Adult Participants

  Incyte Corporation · completed · Healthy Participants · study director
• Ph1/Ph2
  NCT06873789 · A Study to Evaluate INCB177054 in Participants With Select Advanced or Metastatic Solid Tumors

  Incyte Corporation · terminated · Solid Tumors, Advanced Solid Tumors, Metastatic Solid Tumors · study director
• Ph3
  NCT06855498 · Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib

  Incyte Corporation · recruiting · Hidradenitis Suppurativa (HS) · study director
• Ph1/Ph2
  NCT06843408 · A Ph1b/2 Study of Axatilimab Monotherapy in Chinese Participants With Recurrent or Refractory cGVHD

  Incyte Corporation · active not recruiting · Chronic Graft-versus-host-disease · study director
• Ph3
  NCT06832618 · A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children and Adolescents (6 to <18 Years Old) With Moderate Atopic Dermatitis

  Incyte Corporation · active not recruiting · Atopic Dermatitis · study director
• Ph3
  NCT06821542 · A Study to Evaluate Axatilimab Versus Best Available Therapy in Participants With Chronic Graft Versus Host Disease After at Least 2 Prior Lines of Systemic Therapy

  Incyte Corporation · active not recruiting · Chronic Graft-versus-host-disease · study director
• Ph1
  NCT06818812 · A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation

  Incyte Corporation · active not recruiting · Solid Tumors · study director
• Ph3
  NCT06804811 · A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Children (6 to < 12 Years Old) With Nonsegmental Vitiligo

  Incyte Corporation · recruiting · NonSegmental Vitiligo · study director
• Ph1
  NCT06775327 · Study to Assess Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, & Food Effect of Oral INCB000631 to Healthy Adult Participants

  Incyte Corporation · completed · Healthy Participants · study director
• Ph1
  NCT06713590 · A Study to Evaluate a Single-Dose Subcutaneous Axatilimab Compared With Intravenous Axatilimab in Healthy Participants

  Incyte Corporation · completed · Healthy Participants · study director
• N/A
  NCT06627335 · An Observational Retrospective Cohort Study Being Conducted in Women With Atopic Dermatitis Exposed to Ruxolitinib Cream Versus Topical Corticosteroids During Pregnancy: A US Claims Database Analysis

  Incyte Corporation · recruiting · Pregnancy Related, Atopic Dermatitis · study director
• Ph3
  NCT06615050 · A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203)

  Incyte Corporation · recruiting · Graft-versus-host Disease (GVHD) · study director
• Ph1
  NCT06555081 · A Study to Evaluate the Bioequivalence of Ruxolitinib Extended Release (XR) Tablets With Ruxolitinib Immediate Release (IR) Tablets Administered Orally in Healthy Participants

  Incyte Corporation · completed · Healthy Participants · study director
• Ph3
  NCT06548360 · A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo

  Incyte Corporation · recruiting · NonSegmental Vitiligo · study director
• Ph3
  NCT06516952 · A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1)

  Incyte Corporation · active not recruiting · Prurigo Nodularis · study director
• Ph3
  NCT06516965 · A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2)

  Incyte Corporation · active not recruiting · Prurigo Nodularis · study director
• Ph1
  NCT06505265 · A Study to Evaluate Skin and Plasma Pharmacokinetic of Multiple Doses of Povorcitinib After Oral Administration in Healthy Participants

  Incyte Corporation · completed · Healthy Participants · study director
• Ph1
  NCT06441318 · A Study to Evaluate the Effect of Povorcitinib on the QT/QTc Interval in Healthy Participants

  Incyte Corporation · completed · Healthy Participants · study director
• Ph1
  NCT06416800 · A Study to Assess the Effect of Povorcitinib on Digoxin, Rosuvastatin, and Metformin Pharmacokinetics and the Effect of Probenecid on Povorcitinib Pharmacokinetics When Administered Orally to Healthy Adult Participants

  Incyte Corporation · completed · Healthy Participants · study director
• Ph2
  NCT06388564 · A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease

  Incyte Corporation · active not recruiting · Chronic Graft-versus-host-disease · study director
• Ph1
  NCT06380205 · A Study to Evaluate the Drug Interaction Between Povorcitinib and the Oral Contraceptive Levonorgestrel/Ethinyl Estradiol in Healthy Adult Females

  Incyte Corporation · completed · Healthy Participants · study director
• Ph1
  NCT06310304 · A Study to Evaluate the Relative Bioavailability of Ruxolitinib Extended Release (XR) Tablets Compared With Ruxolitinib Immediate Release (IR) Tablets Administered Orally in Healthy Participants.

  Incyte Corporation · completed · Healthy Participants · study director
• Ph3
  NCT06263478 · A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Axatilimab Monotherapy in Japanese Participants With Recurrent or Refractory Active Chronic Graft-Versus-Host Disease

  Incyte Biosciences Japan GK · active not recruiting · Chronic Graft-versus-host-disease · study director
• Ph3
  NCT06238817 · A Study to Evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis

  Incyte Corporation · completed · Atopic Dermatitis · study director
• Ph3
  NCT06212999 · A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa

  Incyte Corporation · active not recruiting · Hidradenitis Suppurativa (HS) · study director
• Ph1
  NCT06213831 · A Study to Evaluate the Safety and Tolerability of Maximal Use Ruxolitinib Cream

  Incyte Corporation · completed · Prurigo Nodularis · study director
• Ph1
  NCT06179160 · A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation

  Incyte Corporation · recruiting · Solid Tumors · study director
• Ph3
  NCT06113445 · A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V1)

  Incyte Corporation · active not recruiting · NonSegmental Vitiligo · study director
• Ph3
  NCT06113471 · A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V2)

  Incyte Corporation · active not recruiting · NonSegmental Vitiligo · study director
• Ph1
  NCT06039384 · A Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation

  Incyte Corporation · terminated · Advanced Solid Tumors · study director
• Ph1
  NCT06034002 · A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms

  Incyte Corporation · recruiting · Myeloproliferative Neoplasms · study director
• Ph1
  NCT05936359 · A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms

  Incyte Corporation · active not recruiting · Myeloproliferative Neoplasms · study director
• Ph2
  NCT05906628 · Topical Ruxolitinib Evaluation in Chronic Hand Eczema

  Incyte Corporation · completed · Hand Eczema · study director
• Ph2
  NCT05888844 · A Study to Evaluate INCB099280 in Participants With Advanced Cutaneous Squamous Cell Carcinoma

  Incyte Corporation · terminated · Cutaneous Squamous Cell Carcinoma · study director
• Ph2
  NCT05879822 · A Study to Evaluate INCB099280 in Participants With Select Solid Tumors Who Are Immune Checkpoint Inhibitor Naive

  Incyte Corporation · terminated · Advanced Solid Tumor · study director
• Ph2
  NCT04434937 · Open-Label Study of Parsaclisib, in Japanese Participants With Relapsed or Refractory Follicular Lymphoma (CITADEL-213)

  Incyte Biosciences Japan GK · completed · Lymphoma · study director
• Ph1
  NCT04242199 · Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors

  Incyte Corporation · completed · Advanced Solid Tumor, MSI-H/dMMR Tumors, Cutaneous Squamous Cell Carcinoma · study director
• Ph3
  NCT04205812 · Platinum-Based Chemotherapy With/Without INCMGA00012, an Anti-PD-1 Antibody, in Non-Small Cell Lung Cancer

  Incyte Corporation · completed · Metastatic Squamous Non-Small Cell Lung Cancer, Metastatic Nonsquamous Non-Small Cell Lung Cancer · study director
• Ph3
  NCT04203511 · INCMGA00012 in Combination With Chemoradiation in Participants With Stage III Non-Small Cell Lung Cancer (POD1UM-301)

  Incyte Corporation · withdrawn · Non-small Cell Lung Cancer · study director
• Ph2
  NCT04003623 · Efficacy and Safety of Pemigatinib in Participants With Solid Tumors With FGFR Mutations or Translocations (FIGHT-208)

  Incyte Corporation · terminated · Advanced or Metastatic Solid Tumors, FGFR Mutations, FGFR Translocations · study director
• Ph1
  NCT03920839 · INCMGA00012 Plus Chemotherapy in Participants With Advanced Solid Tumors (POD1UM-105)

  Incyte Corporation · withdrawn · Advanced and/or Metastatic Solid Tumors, Stage IIIB Not Amenable to Curative Therapy to Stage IV Non-small Cell Lung Cancer, Advanced/Metastatic Unresectable Malignant Pleural Mesothelioma · study director
• Ph2
  NCT03599713 · A Study of INCMGA00012 in Metastatic Merkel Cell Carcinoma (POD1UM-201)

  Incyte Corporation · completed · Metastatic Merkel Cell Carcinoma · study director
• Ph2
  NCT03597295 · A Study of INCMGA00012 in Squamous Carcinoma of the Anal Canal Following Platinum-Based Chemotherapy (POD1UM-202)

  Incyte Corporation · completed · Squamous Cell Carcinoma of Anal Canal · study director
• Ph1
  NCT03059823 · A Phase 1 Study of INCMGA00012 in Patients With Advanced Solid Tumors

  Incyte Corporation · completed · Locally Advanced Solid Tumors, Metastatic Solid Tumors · study director

Grants

NIH projects from RePORTER, fetched 2026-11-11 21:47 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.

No NIH project could be tied to this name by a shared trial or a matching institution.